Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Gossman

Emergency Medical Services Omaha, NE Medical Doctor

NPI 1053385815 CMS profile 138152

601 N 30Th St, Omaha, NE 68131

Open in the dashboard

General payments

$5,272

13 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Gossman of Omaha, NE is reported in the CMS Open Payments database as having received $5,272 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Emergency Medical Services profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $116 2
2024 General $150 2
2023 General $214 2
2022 General $250 2
2021 General $400 1
2020 General $2,016 2
2019 General $2,125 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Gossman
  • Emergency Medical Services median
  • Middle half of Emergency Medical Services
  • National median

In program year 2025, general payments to William Gossman were reported at $116. Among 443 Emergency Medical Services profiles paid that year, the median was $72 and the middle half received between $25 and $169.

Show as a table
Year William Gossman Emergency Medical Services median Middle half National median
2019 $2,125 $62 $20–$162 $163
2020 $2,016 $37 $17–$119 $114
2021 $400 $58 $20–$133 $132
2022 $250 $61 $21–$156 $149
2023 $214 $58 $21–$173 $160
2024 $150 $62 $24–$161 $164
2025 $116 $72 $25–$169 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cardinal Health 110, LLC $5,100 9 payments
  2. Melinta Therapeutics, Inc. $125 1 payment
  3. International Rehabilitative Sciences, Inc $16 1 payment
  4. AstraZeneca Pharmaceuticals LP $16 1 payment
  5. BioXcel Therapeutics, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $5,100 9 payments
  2. Food and Beverage $172 4 payments
Products named General payments · program years 2019–2025
  1. Orbactiv $125 1 payment
  2. RS-4i Plus with Intersperse $16 1 payment
  3. LOKELMA $16 1 payment
  4. IGALMI $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

31,618

Median for Emergency Medicine: 88

Drug cost

$6,105,483

Median for Emergency Medicine: $590

Branded share of claims

100%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 8,063 $2,114,612
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 11,229 $2,106,343
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 4,854 $1,367,221
Boostrix Tdap Diphth,pertuss(Acell),tet Vac Brand 5,963 $353,405
Twinrix Hepatitis A And B Vaccine/Pf Brand 918 $111,006
Adacel Tdap Diph,pertuss(Acell),tet Vac/Pf Brand 319 $17,767
Yf-Vax Yellow Fever Vaccine Live/Pf Brand 39 $7,434
Havrix Hepatitis A Virus Vaccine/Pf Brand 69 $6,078
Typhim Vi Typhoid Vi Polysacch Vaccine Brand 46 $5,292
Mresvia Rsv Vaccine, Pref, Mrna/Pf Brand 15 $4,652

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$48,726

Of which drugs: $5,443

Medicare patients

72

Average age 73

Services billed

6,670

44 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Chronic kidney disease 31%
Diabetes 24%
Ischemic heart disease 24%
Depression 19%
Osteoporosis 17%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Infusion, normal saline solution , 1000 cc J7030 Office 19 47 $97

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medical Services in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record